Progestins in the Medical Management of Endometriosis

Pratibha Singh, Shuchita Batra
In: Journal of medical research/˜The œjournal of medical research · 2017 · vol. 1(3) · W2778760880
article OA: closed CC0 ⤵ 1 in-corpus citation Metadata only
View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This review discusses dienogest and other progestins for endometriosis management, comparing their efficacy, pharmacology, and profiles to existing treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a chronic and debilitating disease affecting a large number of women. It is one of the important etiology of chronic pelvic pain and dysmenorrhea. Prevalence is more in women with infertility. It poses a major challenge for clinicians as there is no permanent cure and even after definitive management, there are high chances of recurrence. The classical triad of dysmenorrhea, dyspareunia and infertility as an important diagnostic feature present in these women. As it affects all the aspects of life of affected woman, a lot of research is directed to find out ideal medication for endometriosis, which has good efficacy, is tolerable, cost-effective, easily available, which targets the basic pathology of disease and cures it. However, such cure is yet to be found. Very similar to ideal agent is a new novel molecule, Dienogest. Its profile is discussed here along with the various studies showing its efficacy and pharmacology and comparison with other progestins already being used since long. Other potential progestins are also discussed providing a whole spectrum of drugs with different efficacy and profiles.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paindysmenorrheadyspareuniainfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (55)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK